H. Raftopoulos

发表

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

S. Novello, E. Felip, E. Esteban, 2018, The New England journal of medicine.

Carcinoma of the lung and metastatic disease of the central nervous system.

J. Austin, C. Powell, G. Pearson, 2008, American journal of respiratory and critical care medicine.

A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors

C. Verschraegen, C. Sweeney, H. Raftopoulos, 2007 .

Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit

R. Gralla, F. Cognetti, D. Giannarelli, 2005 .

LBA49Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

L. Sequist, H. Borghaei, S. Jalal, 2017 .

Competitive repopulation of retrovirally transduced haemopoietic stem cells

H. Raftopoulos, C. Hesdorffer, A. Bank, 1999, British journal of haematology.

Diagnosis and management of hyponatremia in cancer patients

H. Raftopoulos, 2007, Supportive Care in Cancer.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

H. Muss, A. Rodgers, F. Skobieranda, 2005, Cancer.

The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC “Neutropenia, Infection and Myelosuppression” Study Group during the MASCC annual meeting held in Berlin on 27–29 June 2013

J. Klastersky, H. Raftopoulos, K. Rolston, 2016, Supportive Care in Cancer.

The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia

J. Klastersky, H. Raftopoulos, B. Rapoport, 2013, Supportive Care in Cancer.

Oncologists as primary palliative care providers.

H. Raftopoulos, M. Hoffman, R. Roy, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Joseph F. Murphy, V. Thorsson, F. Marincola, 2019, Journal of Immunotherapy for Cancer.

Long-Term Transfer and Expression of the Human β-Globin Gene in a Mouse Transplant Model

H. Raftopoulos, P. Leboulch, A. Bank, 1997 .

A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck

M. Loda, G. Shapiro, V. Latham, 2004, Clinical Cancer Research.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.

R. Gralla, M. Milella, F. Cognetti, 2009, Lung cancer.

Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen.

T. Townes, H. Raftopoulos, A. Bank, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pembrolizumab in Combination With Erlotinib or Gefitinib as First‐Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

L. Sequist, A. Patnaik, J. Yang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Retroviral Vectors Aimed at the Gene Therapy of Human β‐Globin Gene Disorders a

C. Kalberer, R. Humphries, T. Bachelot, 1998 .

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2019, Lung cancer.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

L. Sequist, H. Borghaei, A. Patnaik, 2018, Lung cancer.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

R. Gralla, H. Muss, A. Rodgers, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New Studies.

R. Gralla, H. Raftopoulos, 2009, Journal of oncology practice.

Antiemetic studies on the NK1 receptor antagonist aprepitant.

H. Raftopoulos, John P Stoutenburg, 2004, The Journal of the National Comprehensive Cancer Network.

First-Generation 5-HT3 Receptor Antagonists

K. Deng, H. Raftopoulos, Roy Chen, 2016 .

Supportive care in lung cancer.

H. Raftopoulos, M. Boyar, 2005, Hematology/oncology clinics of North America.

A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy.

M. Puccio, H. Raftopoulos, R. Knight, 2011, Journal of Clinical Oncology.

Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

R. Gralla, N. Gabrail, H. Raftopoulos, 2014, Supportive Care in Cancer.

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

L. Sequist, H. Borghaei, A. Patnaik, 2016 .

Molecular testing in lung cancer: Fine‐needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication

H. Raftopoulos, Weisheng Xu, Chiara Sugrue, 2014, Cancer cytopathology.

Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

L. Sequist, H. Borghaei, S. Jalal, 2016 .

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2016 .

Assessing two meta-analysis (MA) methods: Individual patient data-based (IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 patients (pts)-Are there differences of concern?

R. Gralla, M. Milella, F. Cognetti, 2011, Journal of Clinical Oncology.

Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.

D. Petrylak, U. Swami, S. Goel, 2010 .

Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients.

R. Gralla, H. Raftopoulos, N. Zojwalla, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐Level Transfer and Long‐Term Expression of the Human β‐Globin Gene in a Mouse Transplant Model a

H. Raftopoulos, A. Bank, M. Ward, 1998, Annals of the New York Academy of Sciences.

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

S. Novello, E. Felip, E. Esteban, 2018, Clinical Trials.

OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update

L. Sequist, H. Borghaei, S. Jalal, 2017 .

First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

L. Sequist, H. Borghaei, S. Jalal, 2017 .

Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.

R. Gralla, H. Raftopoulos, R. Boccia, 2015, Future oncology.

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

S. Novello, E. Felip, E. Esteban, 2018, The New England journal of medicine.

Comparing two methods of meta-analysis in clinical research - individual patient data-based (IPD) and literature-based abstracted data (AD) methods: Analyzing five oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs)

R. Gralla, D. Giannarelli, H. Raftopoulos, 2007 .

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

Molecular testing in lung cancer: Fine‐needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication

H. Raftopoulos, Weisheng Xu, Chiara Sugrue, 2014, Cancer cytopathology.